PT3452454T - Moduladores da via integrada ao stresse - Google Patents

Moduladores da via integrada ao stresse

Info

Publication number
PT3452454T
PT3452454T PT177242054T PT17724205T PT3452454T PT 3452454 T PT3452454 T PT 3452454T PT 177242054 T PT177242054 T PT 177242054T PT 17724205 T PT17724205 T PT 17724205T PT 3452454 T PT3452454 T PT 3452454T
Authority
PT
Portugal
Prior art keywords
modulators
integrated stress
stress pathway
pathway
integrated
Prior art date
Application number
PT177242054T
Other languages
English (en)
Original Assignee
Abbvie Inc
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Calico Life Sciences Llc filed Critical Abbvie Inc
Publication of PT3452454T publication Critical patent/PT3452454T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT177242054T 2016-05-05 2017-05-05 Moduladores da via integrada ao stresse PT3452454T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662332284P 2016-05-05 2016-05-05

Publications (1)

Publication Number Publication Date
PT3452454T true PT3452454T (pt) 2020-10-12

Family

ID=58710114

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177242054T PT3452454T (pt) 2016-05-05 2017-05-05 Moduladores da via integrada ao stresse

Country Status (12)

Country Link
US (2) US10864196B2 (pt)
EP (2) EP3778575A1 (pt)
JP (2) JP6869331B2 (pt)
CN (1) CN109641853A (pt)
AR (1) AR108394A1 (pt)
AU (1) AU2017260363B2 (pt)
CA (1) CA3023161A1 (pt)
ES (1) ES2821790T3 (pt)
PT (1) PT3452454T (pt)
TW (1) TW201808914A (pt)
UY (1) UY37231A (pt)
WO (1) WO2017193030A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN112713985B (zh) 2017-05-05 2022-03-08 华为技术有限公司 传输信号的方法和装置
CA3063729A1 (en) * 2017-05-15 2018-11-22 Recurium Ip Holdings, Llc Analgesic compounds
JP2020522553A (ja) * 2017-06-07 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Atf4経路阻害剤としての化合物
WO2018225093A1 (en) * 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
MX2020001352A (es) 2017-08-09 2020-03-20 Denali Therapeutics Inc Compuestos, composiciones y metodos.
BR112020008827A2 (pt) * 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
CN112218851A (zh) * 2017-11-02 2021-01-12 卡里科生命科学有限责任公司 整合应激通路的调节剂
RU2020122711A (ru) 2017-12-13 2022-01-17 ПРАКСИС БАЙОТЕК ЭлЭлСи Ингибиторы пути интегрированной реакции на стресс
EP3768660A1 (en) * 2018-03-23 2021-01-27 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
AU2019282253A1 (en) 2018-06-05 2020-11-26 Altos Labs, Inc. Inhibitors of integrated stress response pathway
EP3849979A1 (en) 2018-09-12 2021-07-21 Novartis AG Antiviral pyridopyrazinedione compounds
TWI832295B (zh) 2018-10-11 2024-02-11 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
TW202045164A (zh) 2019-02-13 2020-12-16 美商戴納立製藥公司 化合物、組合物及方法
WO2020167994A1 (en) * 2019-02-13 2020-08-20 Denali Therapeutics Inc. Compounds, compositions and methods
WO2020216766A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2021012904A (es) * 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
EP3962906A1 (en) 2019-04-30 2022-03-09 Calico Life Sciences LLC Substituted cycloalkyls as modulators of the integrated stress pathway
EP3982965A4 (en) 2019-06-12 2023-01-25 Praxis Biotech LLC INTEGRATED STRESS RESPONSE PATHWAY MODULATORS
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
WO2021127643A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US20230125481A1 (en) 2020-01-28 2023-04-27 Evotec International Gmbh Modulators of the integrated stress response pathway
JP2023517944A (ja) 2020-03-11 2023-04-27 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合的ストレス応答経路の調節因子
EP4232447A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
US20230391725A1 (en) 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
JP2023546225A (ja) 2020-10-22 2023-11-01 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合ストレス応答経路のモジュレーター
WO2024109736A1 (zh) * 2022-11-21 2024-05-30 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其合成方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US162A (en) 1837-04-17 Island
US5212A (en) 1847-07-31 Richard m
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
CN101475538A (zh) * 2002-12-20 2009-07-08 默克公司 用作11-β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
BRPI0606228A2 (pt) 2005-01-05 2009-06-09 Abbott Lab inibidores de enzima 11-beta-hidroxiesteróide desidrogenase tipo 1
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
US8334290B2 (en) * 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
WO2011087758A1 (en) 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
TWI538905B (zh) 2010-12-22 2016-06-21 H 朗德貝克公司 雙環[3.2.1]辛基醯胺衍生物及其用途
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア eIF2α経路の調節因子
US20160318856A1 (en) * 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators
JP7049276B2 (ja) * 2016-06-24 2022-04-06 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピンおよびその結合体

Also Published As

Publication number Publication date
WO2017193030A1 (en) 2017-11-09
EP3452454B1 (en) 2020-07-08
US20210113532A1 (en) 2021-04-22
US10864196B2 (en) 2020-12-15
CA3023161A1 (en) 2017-11-09
UY37231A (es) 2017-11-30
ES2821790T3 (es) 2021-04-27
JP6869331B2 (ja) 2021-05-12
EP3778575A1 (en) 2021-02-17
US20190142806A1 (en) 2019-05-16
ES2821790T8 (es) 2022-01-03
TW201808914A (zh) 2018-03-16
JP2021107415A (ja) 2021-07-29
AU2017260363B2 (en) 2021-12-02
AU2017260363A1 (en) 2018-11-15
EP3452454A1 (en) 2019-03-13
CN109641853A (zh) 2019-04-16
AR108394A1 (es) 2018-08-15
JP2019515042A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
IL274369A (en) Combined pressure pathway modulators
IL274405A (en) Combined pressure pathway modulators
IL274368A (en) Combined pressure pathway modulators
PT3452454T (pt) Moduladores da via integrada ao stresse
SI3452448T1 (sl) Modulatorji integrirane stresne poti
IL274406A (en) Combined pressure pathway modulators
IL274367A (en) Combined pressure pathway modulators
IL283582A (en) ror - gamma modulators
IL262303A (en) Modulators of nlrp3
HK1256599A1 (zh) ROR-γ的調節劑
IL282153B1 (en) Pro-drugs that modulate pathways of combined stress
IL271935A (en) NLRP3 modulators
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
IL266265A (en) Functional chocolate
IL266261A (en) ror-gamma modulators
GB201716468D0 (en) Modulators
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORγ)
GB2563095B (en) Modulators
GB2549084B (en) Fixing
GB201702926D0 (en) Modulators
GB201609238D0 (en) Stress response
GB201614045D0 (en) Microcapsules
AU367218S (en) Chocolate